Dollar change -0.0004
Percentage change -0.50	%

Peers: IOVA FATE ALLO ADPT BLRX CGEN AFMD IMTX TPST

| Held by: SPDW GWX

Index	-	P/E	-	EPS (ttm)	-0.27	Insider Own	10.94%	Shs Outstand	257.85M	Perf Week	-76.97%
Market Cap	20.60M	Forward P/E	-	EPS next Y	-0.14	Insider Trans	-69.43%	Shs Float	229.65M	Perf Month	-67.04%
Enterprise Value	9.75M	PEG	-	EPS next Q	-0.05	Inst Own	34.04%	Short Float	1.69%	Perf Quarter	-70.96%
Income	-69.49M	P/S	0.11	EPS this Y	-60.00%	Inst Trans	-23.30%	Short Ratio	0.74	Perf Half Y	-86.88%
Sales	180.20M	P/B	-	EPS next Y	-73.21%	ROA	-33.40%	Short Interest	3.88M	Perf YTD	-85.17%
Book/sh	-0.15	P/C	0.35	EPS next 5Y	-	ROE	-273.36%	52W High	1.36 -94.13%	Perf Year	-93.85%
Cash/sh	0.23	P/FCF	-	EPS past 3/5Y	34.83% 26.53%	ROIC	-1045.00%	52W Low	0.08 5.69%	Perf 3Y	-95.63%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	207.12% 175.28%	Gross Margin	93.44%	Volatility	26.68% 11.96%	Perf 5Y	-99.12%
Dividend TTM	-	EV/Sales	0.05	EPS Y/Y TTM	62.93%	Oper. Margin	-31.13%	ATR (14)	0.03	Perf 10Y	-99.49%
Dividend Ex-Date	-	Quick Ratio	1.79	Sales Y/Y TTM	883.05%	Profit Margin	-38.56%	RSI (14)	25.75	Recom	3.29
Dividend Gr. 3/5Y	- -	Current Ratio	2.02	EPS Q/Q	7.24%	SMA20	-65.83%	Beta	2.18	Target Price	1.01
Payout	-	Debt/Eq	-	Sales Q/Q	28.87%	SMA50	-68.27%	Rel Volume	15.75	Prev Close	0.08
Employees	506	LT Debt/Eq	-	Earnings	May 13 BMO	SMA200	-82.55%	Avg Volume	5.26M	Price	0.08
IPO	May 06, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	64.79% 3.21%	Trades		Volume	82,874,513	Change	-0.50%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-26-25	Downgrade	Mizuho	Outperform → Neutral	$0.50
Jul-30-24	Initiated	H.C. Wainwright	Buy	$4
May-30-24	Initiated	Scotiabank	Sector Outperform	$3.15
Mar-24-23	Initiated	Bryan Garnier	Buy	$3.60
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$5
Nov-09-22	Upgrade	Mizuho	Neutral → Buy	$9
May-28-21	Initiated	Barclays	Underweight	$4
Apr-22-20	Initiated	Mizuho	Neutral	$3
Aug-02-19	Downgrade	Guggenheim	Buy → Neutral
May-31-19	Initiated	ROTH Capital	Buy
May-30-19	Resumed	Citigroup	Buy
May-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform	$12 → $5
Mar-17-17	Initiated	Wells Fargo	Market Perform
Oct-24-16	Downgrade	BofA/Merrill	Neutral → Underperform
Sep-30-16	Initiated	Raymond James	Outperform	$16
Feb-25-16	Initiated	Citigroup	Buy	$15
Jun-01-15	Initiated	Leerink Partners	Outperform	$24
Jun-01-15	Initiated	Guggenheim	Buy
Jun-01-15	Initiated	BofA/Merrill	Neutral

Show Previous Ratings

Jul-28-25 07:30AM	Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds (Newsfile) -71.17%
Jun-26-25 09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
May-14-25 03:05AM	Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch ... (GuruFocus.com) +8.80%
May-13-25 07:30AM	Adaptimmune Reports Q1 Financial Results and Provides Business Update (Newsfile) -15.31%
May-12-25 09:48AM	What To Expect From Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings (GuruFocus.com)
12:00PM	Loading…
May-07-25 12:00PM	Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025 (Newsfile)
Mar-21-25 12:05PM	Earnings To Watch: Adaptimmune Therapeutics PLC (ADAP) Reports Q4 2024 Result (GuruFocus.com)
03:01AM	Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ... (GuruFocus.com)
Mar-20-25 12:10PM	Adaptimmune targets $400M sarcoma franchise peak sales by 2027 (SeekingAlpha) -37.65%
12:10PM	Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:00AM	Adaptimmune Provides Q4 and Full Year 2024 Business Update (Newsfile)
Mar-19-25 06:00PM	Here's the major earnings before the open tomorrow (SeekingAlpha)
Mar-18-25 07:00AM	From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines (FastCompany)
Mar-12-25 04:54PM	Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025 (Newsfile)
Jan-30-25 04:00PM	Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 (Newsfile)
08:00AM	Loading…
Jan-13-25 08:00AM	Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS) (Newsfile)
Dec-19-24 07:30AM	Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK (Newsfile)
Dec-02-24 04:00PM	First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel) (Newsfile)
Nov-15-24 05:00AM	Halozyme bids for Evotec; BeiGene gets a new name (BioPharma Dive)
Nov-14-24 11:55AM	Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints (Pharmaceutical Technology) -23.28%
02:15AM	Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ... (GuruFocus.com)
Nov-13-24 04:05PM	Adaptimmune Reports Q3 2024 Financial and Business Updates (Newsfile)
09:00AM	Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial (Newsfile)
Nov-05-24 09:19AM	Adaptimmune to Participate in Scientific and Medical Conferences this November and December (Newsfile)
Oct-31-24 05:20PM	Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024 (Newsfile) +10.23%
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire) -5.41%
Aug-28-24 08:00AM	Adaptimmune to Participate in Two Bank Conferences this September (Newsfile)
Aug-12-24 07:00AM	Adaptimmune Reports Q2 2024 Financial and Business Updates (Newsfile) +9.82%
Aug-09-24 07:13AM	Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval (Pharmaceutical Technology)
08:00AM	Loading…
Aug-05-24 08:00AM	Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024 (Newsfile) -16.24%
Aug-02-24 11:53AM	Adaptimmunes Tecelra gains accelerated approval for synovial sarcoma (Pharmaceutical Technology) -7.87%
08:46AM	FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade (Benzinga)
06:54AM	First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer (BioPharma Dive)
Aug-01-24 08:20PM	Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor (Business Wire)
Jul-24-24 11:13PM	Why Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now? (Insider Monkey) +5.69%
Jul-03-24 11:11AM	3 Biotech Moonshots With Imminent Catalyst Potential (InvestorPlace)
06:00AM	5 FDA decisions to watch in the third quarter (BioPharma Dive)
Jun-03-24 12:00PM	Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise (Newsfile) -5.31%
May-31-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +11.88%
May-30-24 04:01PM	Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications (GlobeNewswire)
04:01PM	Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications (Newsfile)
May-17-24 06:49AM	Mizuho Slashes Price Target on Adaptimmune Therapeutics to $3 From $9, Keeps Buy Rating (MT Newswires) -7.50%
May-16-24 08:18AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-15-24 12:53PM	ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +7.83%
11:07AM	Adaptimmune Therapeutics Enters Into $125 Million Term Loan Facility With Hercules Capital (MT Newswires)
07:30AM	Adaptimmune Reports Q1 2024 Financial and Business Updates (Newsfile)
07:00AM	Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital (Newsfile)
May-01-24 12:00PM	Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024 (Newsfile)
Apr-23-24 07:45AM	Garry Menzel joins GHO Capital as Operating Partner (GlobeNewswire) +12.87%
Apr-15-24 02:12PM	Adaptimmune (ADAP) Down on End of Collaboration With Roche (Zacks) -9.48%
Apr-12-24 08:00AM	Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated (Newsfile) -10.08%
05:37AM	Roche, Adaptimmune part ways on cell therapy research (BioPharma Dive)
Mar-27-24 07:30PM	Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet (Newsfile)
Mar-07-24 01:42PM	Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
08:24AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 12:52PM	ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) +17.12%
07:00AM	Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates (Newsfile)
Feb-27-24 08:00AM	Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise (Newsfile)
Feb-21-24 04:00PM	Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024 (Newsfile) +19.05% -8.00%
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey)
Feb-13-24 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know (Zacks) +7.11%
Jan-31-24 04:44PM	Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review (Newsfile) +9.74%
Jan-30-24 01:02PM	Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC (GuruFocus.com) +10.18%
Jan-16-24 11:17AM	Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why (Zacks) -13.72%
Jan-04-24 07:37AM	Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference (Newsfile) +12.40%
Dec-06-23 07:00AM	Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma (Newsfile)
Nov-30-23 10:52AM	Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND (Zacks)
Nov-29-23 08:00AM	Adaptimmune Receives Transfer of IND for Lete-cel Program (Newsfile) +11.66%
Nov-13-23 09:35AM	Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:35AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:30AM	Adaptimmune Reports Third Quarter Financial Results and Business Update (Newsfile) -5.57%
07:05AM	Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy (Newsfile)
Nov-07-23 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Oct-31-23 08:00AM	Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS (Newsfile)
08:00AM	Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control (Newsfile)
Oct-27-23 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
Oct-25-23 08:06AM	Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023 (Newsfile)
Oct-23-23 04:15AM	Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO (Newsfile) +6.25%
Sep-11-23 08:00AM	Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development (Newsfile) +8.81%
Aug-09-23 07:29AM	Adaptimmune Reports Second Quarter Financial Results and Business Update (Newsfile)
Aug-03-23 01:24PM	Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023 (Newsfile)
Jul-28-23 12:30PM	Adaptimmune (ADAP) to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-20-23 07:28AM	Investors in Adaptimmune Therapeutics (NASDAQ:ADAP) from five years ago are still down 90%, even after 12% gain this past week (Simply Wall St.) -10.10%
Jul-16-23 08:18PM	Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains? (Zacks)
Jun-29-23 09:18AM	Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7% (Zacks)
Jun-26-23 11:23AM	AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval (Zacks)
11:15AM	Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data (Zacks)
Jun-23-23 09:15AM	Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal (Zacks)
Jun-22-23 09:40AM	Amgen's (AMGN) Blincyto sBLA Gets FDA Nod in Treating Leukemia (Zacks)
Jun-19-23 10:18AM	GSK Announces Extension of FDA Review for Rare Blood Therapy (Zacks)
Jun-16-23 08:39AM	Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study (Zacks)
Jun-15-23 09:43AM	Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall (Zacks)
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-13-23 10:14AM	AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review (Zacks)
Jun-12-23 10:00AM	Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies (Zacks) +5.33%
09:48AM	AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies (Zacks)
Jun-09-23 10:52AM	Merck's (MRK) Keytruda for Liver Cancer to Undergo FDA Review (Zacks)
Jun-06-23 06:50AM	Dr. Reddy's (RDY) Meets Goals in Actemra Biosimilar Study (Zacks)
Jun-05-23 11:40AM	Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros (Zacks)

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EcoR1 Capital, LLC	10% Owner	Jul 28 '25	Sale	0.11	33,931,740	3,817,321	130,492,680	Jul 30 06:20 PM
EcoR1 Capital, LLC	10% Owner	Jul 30 '25	Sale	0.10	27,433,338	2,800,944	100,371,882	Jul 30 06:20 PM
EcoR1 Capital, LLC	10% Owner	Jul 29 '25	Sale	0.10	2,687,460	271,971	127,805,220	Jul 30 06:20 PM
Norry Elliot	Chief Medical Officer	Jan 17 '25	Sale	0.58	5,584	3,243	7,510	Jan 17 09:17 PM
Lunger John	Chief Patient Supply Officer	Jan 17 '25	Sale	0.58	5,584	3,243	7,510	Jan 17 09:17 PM
Bertrand William C JR	Chief Operating Officer	Jan 17 '25	Sale	0.58	5,584	3,243	7,510	Jan 17 09:16 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 17 '25	Sale	0.58	30,601	17,773	44,327	Jan 17 09:15 PM
Norry Elliot	Chief Medical Officer	Jan 17 '25	Proposed Sale	0.58	5,584	3,243		Jan 17 03:07 PM
Lunger John	Chief Patient Supply Officer	Jan 17 '25	Proposed Sale	0.58	5,584	3,243		Jan 17 02:59 PM
Bertrand William C JR	Chief Operating Officer	Jan 17 '25	Proposed Sale	0.58	5,584	3,243		Jan 17 02:50 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 17 '25	Proposed Sale	0.58	30,601	17,772		Jan 17 02:42 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 13 '25	Sale	0.59	30,473	17,915	17,801	Jan 15 04:19 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 15 '25	Sale	0.57	29,096	16,724	41,582	Jan 15 04:19 PM
Piccina Cintia	Chief Commercial Officer	Jan 15 '25	Sale	0.57	12,991	7,467	18,421	Jan 15 04:18 PM
Norry Elliot	Chief Medical Officer	Jan 13 '25	Sale	0.59	12,392	7,285	5,845	Jan 15 04:17 PM
Norry Elliot	Chief Medical Officer	Jan 15 '25	Sale	0.57	9,803	5,635	13,756	Jan 15 04:17 PM
Lunger John	Chief Patient Supply Officer	Jan 13 '25	Sale	0.59	9,739	5,726	5,845	Jan 15 04:16 PM
Lunger John	Chief Patient Supply Officer	Jan 15 '25	Sale	0.57	9,803	5,635	13,756	Jan 15 04:16 PM
Bertrand William C JR	Chief Operating Officer	Jan 13 '25	Sale	0.59	9,739	5,726	5,845	Jan 15 04:15 PM
Bertrand William C JR	Chief Operating Officer	Jan 15 '25	Sale	0.57	9,803	5,635	13,756	Jan 15 04:15 PM
Bertrand William C JR	Chief Operating Officer	Jan 13 '25	Proposed Sale	0.59	9,739	5,726		Jan 15 04:01 PM
Piccina Cintia	Chief Commercial Officer	Jan 15 '25	Proposed Sale	0.57	12,991	7,467		Jan 15 03:55 PM
Norry Elliot	Chief Medical Officer	Jan 13 '25	Proposed Sale	0.59	12,392	7,286		Jan 15 03:50 PM
Lunger John	Chief Patient Supply Officer	Jan 13 '25	Proposed Sale	0.59	9,739	5,726		Jan 15 03:43 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 13 '25	Proposed Sale	0.59	30,473	17,917		Jan 15 03:34 PM

Open in Screener

ZYME

Zymeworks BC Inc

Aug 01 • 04:00PM ET

12.57

Dollar change +0.01
Percentage change 0.08	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB GILD REGN VRTX INCY ALNY EXEL NBIX IONS

| Held by: VTI IWM IWO IBB VTWO DFAS DFAC VHT IWC ONEQ

Index	RUT	P/E	-	EPS (ttm)	-1.50	Insider Own	3.58%	Shs Outstand	69.58M	Perf Week	-5.70%
Market Cap	883.09M	Forward P/E	-	EPS next Y	-1.25	Insider Trans	-	Shs Float	67.74M	Perf Month	-2.48%
Enterprise Value	636.26M	PEG	-	EPS next Q	-0.49	Inst Own	109.09%	Short Float	10.14%	Perf Quarter	-2.41%
Income	-113.68M	P/S	9.46	EPS this Y	5.82%	Inst Trans	22.14%	Short Ratio	15.20	Perf Half Y	-14.72%
Sales	93.38M	P/B	2.71	EPS next Y	18.16%	ROA	-23.22%	Short Interest	6.87M	Perf YTD	-14.14%
Book/sh	4.63	P/C	3.33	EPS next 5Y	-4.21%	ROE	-29.80%	52W High	17.70 -28.98%	Perf Year	20.63%
Cash/sh	3.78	P/FCF	-	EPS past 3/5Y	26.71% 15.81%	ROIC	-33.42%	52W Low	9.03 39.20%	Perf 3Y	114.14%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	41.95% 20.90%	Gross Margin	86.95%	Volatility	4.33% 4.19%	Perf 5Y	-58.99%
Dividend TTM	-	EV/Sales	6.81	EPS Y/Y TTM	15.96%	Oper. Margin	-115.26%	ATR (14)	0.57	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.71	Sales Y/Y TTM	85.05%	Profit Margin	-121.73%	RSI (14)	40.67	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	4.71	EPS Q/Q	27.42%	SMA20	-7.02%	Beta	1.26	Target Price	22.17
Payout	-	Debt/Eq	0.06	Sales Q/Q	170.29%	SMA50	-1.66%	Rel Volume	1.41	Prev Close	12.56
Employees	286	LT Debt/Eq	0.05	Earnings	Aug 07 AMC	SMA200	-5.03%	Avg Volume	452.01K	Price	12.57
IPO	Apr 28, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	56.11% 31.53%	Trades		Volume	637,973	Change	0.08%

Date	Action	Analyst	Rating Change	Price Target Change
May-20-25	Initiated	TD Cowen	Buy
Dec-16-24	Upgrade	JP Morgan	Neutral → Overweight	$18
Nov-07-24	Upgrade	Leerink Partners	Market Perform → Outperform	$10 → $25
Nov-01-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$12
Mar-21-23	Resumed	Wells Fargo	Overweight	$12
Jan-04-23	Reiterated	H.C. Wainwright	Neutral	$10 → $8
Dec-20-22	Upgrade	Jefferies	Hold → Buy	$7.70 → $11
Nov-01-22	Downgrade	H.C. Wainwright	Buy → Neutral	$40 → $8
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$8
Oct-04-22	Resumed	Wells Fargo	Overweight	$45 → $9
May-05-22	Upgrade	Guggenheim	Neutral → Buy	$14
Mar-15-22	Initiated	Evercore ISI	Outperform	$15
Dec-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-17-21	Resumed	Guggenheim	Neutral
Oct-07-21	Initiated	Jefferies	Hold	$32
Mar-31-21	Initiated	Credit Suisse	Outperform	$55
Feb-25-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$41
Feb-08-21	Resumed	H.C. Wainwright	Buy	$57
Jan-25-21	Downgrade	Citigroup	Buy → Neutral	$50 → $53
Sep-29-20	Resumed	JP Morgan	Neutral	$48

Show Previous Ratings

Jul-29-25 11:03AM	Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and More (GlobeNewswire)
Jul-28-25 06:00AM	Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate (GlobeNewswire)
Jul-18-25 09:58AM	Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains? (Zacks)
Jul-17-25 06:00AM	Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 (GlobeNewswire) +7.10%
Jul-10-25 12:00PM	Life Sciences BC Announces 2025 Awards Winners, Honouring Excellence in Health Innovation (Business Wire)
12:00PM	Loading…
Jun-20-25 12:00PM	All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy (Zacks)
Jun-04-25 09:55AM	Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High? (Zacks)
May-30-25 06:00AM	Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer (GlobeNewswire)
May-22-25 05:00PM	Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences (GlobeNewswire)
May-21-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-19-25 04:15PM	Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference (GlobeNewswire) +5.16%
May-14-25 09:55AM	Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet (Zacks)
May-08-25 05:50PM	Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 10:35AM	Zymeworks Inc (ZYME) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
06:33PM	Loading…
Apr-30-25 06:33PM	Hope Amidst The Madness As Market Avoids A New Low (Seeking Alpha)
Apr-28-25 05:33PM	Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline (Seeking Alpha)
10:48AM	Zymeworks: Poised For Growth With Platform Validation (Seeking Alpha)
Apr-25-25 01:00PM	Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting (GlobeNewswire)
Apr-21-25 06:00AM	Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development (GlobeNewswire)
Apr-17-25 06:00AM	Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 (GlobeNewswire)
Apr-09-25 10:13AM	Zymeworks Inc. (ZYME): Among Stocks Insiders Bought in April After Trump's Tariff Rollout (Insider Monkey)
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Mar-26-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Mar-25-25 04:30PM	Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting (GlobeNewswire)
10:49AM	Zymeworks Inc. (ZYME): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
Mar-05-25 04:05PM	Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -7.97%
Mar-04-25 07:09AM	Zymeworks Inc (ZYME) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-26-25 06:00AM	Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration (GlobeNewswire)
Feb-25-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
06:00AM	Loading…
Feb-18-25 06:00AM	Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors (GlobeNewswire)
Feb-13-25 06:00AM	Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025 (GlobeNewswire)
Jan-30-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-08-25 04:05PM	Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026 (GlobeNewswire) -6.44%
Dec-12-24 08:30AM	Zymeworks Hosts RandD Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases (GlobeNewswire)
08:30AM	Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases (GlobeNewswire)
Nov-21-24 06:05AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire) -5.98%
06:00AM	FDA Grants U.S. Approval of Ziihera (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) (GlobeNewswire)
Nov-05-24 06:00AM	Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-? Expressing Advanced Solid Tumors (GlobeNewswire)
Oct-31-24 04:05PM	Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 09:14AM	Zymeworks Inc (ZYME) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-29-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Oct-25-24 06:00AM	Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference (GlobeNewswire)
Oct-21-24 06:00AM	Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers (GlobeNewswire)
Oct-10-24 06:30AM	Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024 (GlobeNewswire)
Sep-19-24 12:08PM	Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players (PR Newswire)
Sep-18-24 06:00AM	Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference (GlobeNewswire)
Sep-03-24 04:30PM	Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c) (GlobeNewswire)
Aug-22-24 06:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-01-24 04:10PM	Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock (GlobeNewswire)
04:05PM	Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-30-24 06:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jul-25-24 04:30PM	Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer (GlobeNewswire)
Jul-22-24 06:00AM	Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor- Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate (GlobeNewswire)
Jul-11-24 06:30AM	Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024 (GlobeNewswire) +6.82%
Jun-17-24 06:00AM	Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers (GlobeNewswire) -5.53%
Jun-10-24 06:00AM	Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer (GlobeNewswire)
May-28-24 06:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-19-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm (GlobeNewswire)
May-16-24 04:20PM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Zymeworks Inc. (ZYME) (Business Wire)
May-02-24 04:05PM	Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Apr-11-24 06:00AM	Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024 (GlobeNewswire)
Apr-10-24 09:35AM	Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Apr-08-24 06:00AM	Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-28-24 06:00AM	Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors (GlobeNewswire)
Mar-27-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Mar-22-24 12:00PM	Zymeworks (ZYME) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-11-24 12:44PM	20 Highest Paying Countries for Biotechnology (Insider Monkey)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-07-24 06:39AM	Zymeworks halts plans for phase 2 ADC trial to mull 'evolving clinical landscape' (FierceBiotech.com) -6.46%
Mar-06-24 10:53PM	ZYME Stock Earnings: Zymeworks Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:09PM	Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-05-24 04:30PM	Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting (GlobeNewswire)
Feb-28-24 10:00AM	Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for (Zacks) -6.51%
Feb-27-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-24 06:00AM	Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call (GlobeNewswire)
Feb-09-24 08:00AM	InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer (Newsfile)
Feb-08-24 06:00AM	Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors (GlobeNewswire)
Jan-31-24 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-11-24 12:00PM	Zymeworks Inc. (ZYME) Is Up 1.64% in One Week: What You Should Know (Zacks)
Jan-04-24 06:15AM	Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025 (GlobeNewswire)
06:00AM	Zymeworks Announces Additional Leadership Appointments (GlobeNewswire)
Dec-26-23 08:00AM	Zymeworks Announces $50 Million Private Placement to EcoR1 Capital (GlobeNewswire) +8.65%
Dec-15-23 08:30AM	Zymeworks Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-08-23 10:11AM	5 Best Healthcare Stocks For the Long-Term (Insider Monkey)
Nov-30-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conference (GlobeNewswire)
Nov-08-23 05:33PM	Zymeworks Inc. (NYSE:ZYME) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:05PM	Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Oct-17-23 08:30AM	Zymeworks To Host Third Quarter 2023 Results Conference Call (GlobeNewswire)
Oct-16-23 04:30PM	Zymeworks Announces New Director Nominee (GlobeNewswire) +8.46%
Aug-10-23 04:05PM	Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire) -7.60%
Aug-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jul-19-23 08:30AM	Zymeworks To Host Second Quarter 2023 Results Conference Call (GlobeNewswire)
Jul-03-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conference (GlobeNewswire)
Jun-29-23 04:05PM	Zymeworks Appoints New Director (GlobeNewswire)
Jun-26-23 08:30AM	Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes (GlobeNewswire)
Jun-02-23 06:41PM	Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers (PR Newswire)
Jun-01-23 08:30AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EcoR1 Capital, LLC	Director	May 15 '25	Buy	11.43	49,502	565,847	17,877,989	May 19 06:35 PM
EcoR1 Capital, LLC	Director	May 19 '25	Buy	11.78	5,919	69,738	17,883,908	May 19 06:35 PM
EcoR1 Capital, LLC	Director	Apr 16 '25	Buy	11.16	73,953	825,589	17,773,727	Apr 18 03:17 PM
EcoR1 Capital, LLC	Director	Apr 17 '25	Buy	11.52	54,760	630,819	17,828,487	Apr 18 03:17 PM
EcoR1 Capital, LLC	Director	Apr 04 '25	Buy	11.17	196,438	2,193,800	17,699,774	Apr 07 06:34 PM
EcoR1 Capital, LLC	Director	Apr 03 '25	Buy	11.84	120,770	1,430,170	17,503,336	Apr 07 06:34 PM
EcoR1 Capital, LLC	Director	Apr 02 '25	Buy	11.85	74,360	881,017	17,382,566	Apr 02 07:02 PM
EcoR1 Capital, LLC	Director	Apr 01 '25	Buy	11.60	48,658	564,647	17,308,206	Apr 02 07:02 PM
EcoR1 Capital, LLC	Director	Mar 31 '25	Buy	11.75	4,397	51,658	17,259,548	Apr 02 07:02 PM
EcoR1 Capital, LLC	Director	Mar 25 '25	Buy	12.91	53,501	690,452	17,211,303	Mar 27 06:53 PM
EcoR1 Capital, LLC	Director	Mar 26 '25	Buy	12.24	43,848	536,857	17,255,151	Mar 27 06:53 PM
EcoR1 Capital, LLC	Director	Mar 20 '25	Buy	12.93	73,476	949,883	17,104,080	Mar 24 05:45 PM
EcoR1 Capital, LLC	Director	Mar 21 '25	Buy	12.78	31,033	396,518	17,135,113	Mar 24 05:45 PM
EcoR1 Capital, LLC	Director	Mar 24 '25	Buy	13.08	22,689	296,847	17,157,802	Mar 24 05:45 PM
EcoR1 Capital, LLC	Director	Mar 18 '25	Buy	12.65	113,880	1,440,855	16,972,298	Mar 19 06:32 PM
EcoR1 Capital, LLC	Director	Mar 19 '25	Buy	12.64	58,306	737,233	17,030,604	Mar 19 06:32 PM
EcoR1 Capital, LLC	Director	Mar 17 '25	Buy	12.23	56,277	688,465	16,858,418	Mar 19 06:32 PM
EcoR1 Capital, LLC	Director	Mar 13 '25	Buy	12.48	468,356	5,847,237	16,802,141	Mar 13 07:35 PM
EcoR1 Capital, LLC	Director	Mar 11 '25	Buy	11.49	320,690	3,685,851	16,040,851	Mar 13 07:35 PM
EcoR1 Capital, LLC	Director	Mar 12 '25	Buy	12.25	292,934	3,587,826	16,333,785	Mar 13 07:35 PM
EcoR1 Capital, LLC	Director	Jan 16 '25	Buy	13.88	121,681	1,689,541	15,700,413	Jan 21 05:34 PM
EcoR1 Capital, LLC	Director	Jan 17 '25	Buy	13.87	19,748	273,998	15,720,161	Jan 21 05:34 PM
EcoR1 Capital, LLC	Director	Jan 13 '25	Buy	13.39	74,125	992,875	15,485,203	Jan 15 06:12 PM
EcoR1 Capital, LLC	Director	Jan 14 '25	Buy	13.56	54,500	739,265	15,539,703	Jan 15 06:12 PM
EcoR1 Capital, LLC	Director	Jan 15 '25	Buy	14.01	39,029	546,671	15,578,732	Jan 15 06:12 PM
EcoR1 Capital, LLC	Director	Jan 10 '25	Buy	13.13	204,098	2,678,990	15,411,078	Jan 10 06:27 PM
EcoR1 Capital, LLC	Director	Jan 08 '25	Buy	14.07	21,021	295,829	15,206,980	Jan 10 06:27 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 06 '25	Option Exercise	0.00	37,166	0	34,741	Jan 06 08:35 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 06 '25	Sale	14.92	21,200	316,391	14,741	Jan 06 08:35 PM
Galbraith Kenneth	Chair & CEO	Jan 06 '25	Option Exercise	0.00	114,332	0	114,209	Jan 06 08:34 PM
Galbraith Kenneth	Chair & CEO	Jan 06 '25	Sale	14.92	57,291	855,017	47,543	Jan 06 08:34 PM
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 06 '25	Option Exercise	0.00	20,000	0	20,000	Jan 06 08:19 PM
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 06 '25	Sale	14.92	11,110	165,807	8,890	Jan 06 08:19 PM
Smith Jeffrey T L	Officer	Jan 06 '25	Proposed Sale	14.46	11,110	160,651		Jan 06 07:50 PM
Moore Paul Andrew	Officer	Jan 06 '25	Proposed Sale	14.46	21,200	306,552		Jan 06 07:43 PM
Galbraith, Kenneth	Officer	Jan 06 '25	Proposed Sale	14.46	57,291	828,428		Jan 06 07:37 PM
EcoR1 Capital, LLC	Director	Jan 02 '25	Buy	14.78	157,880	2,333,403	15,185,959	Jan 02 05:51 PM
EcoR1 Capital, LLC	Director	Dec 31 '24	Buy	14.57	146,501	2,134,446	15,028,079	Jan 02 05:51 PM
EcoR1 Capital, LLC	Director	Dec 30 '24	Buy	14.47	58,988	853,326	14,881,578	Jan 02 05:51 PM
EcoR1 Capital, LLC	Director	Dec 27 '24	Buy	14.49	101,659	1,473,181	14,822,590	Dec 27 06:41 PM
EcoR1 Capital, LLC	Director	Dec 26 '24	Buy	14.38	16,692	240,038	14,720,931	Dec 27 06:41 PM
EcoR1 Capital, LLC	Director	Dec 24 '24	Buy	14.12	11,958	168,896	14,704,239	Dec 27 06:41 PM

Open in Screener

ITOS

ITeos Therapeutics Inc

Aug 01 • 04:00PM ET

10.09

Dollar change -0.05
Percentage change -0.49	%

Healthcare • Biotechnology • USA • NASD

ITOS ITeos Therapeutics Inc daily Stock Chart

Peers: MRNA AZN BMY GILD AMGN PFE JNJ REGN VRTX INCY

| Held by: VTI IWM VXF IWN IBB VTWO SCHA DFAT FESM VHT

Index	RUT	P/E	-	EPS (ttm)	-3.23	Insider Own	6.26%	Shs Outstand	38.27M	Perf Week	-0.79%
Market Cap	386.18M	Forward P/E	-	EPS next Y	-1.62	Insider Trans	-	Shs Float	35.88M	Perf Month	-0.69%
Enterprise Value	-129.14M	PEG	-	EPS next Q	-1.02	Inst Own	117.87%	Short Float	8.56%	Perf Quarter	34.53%
Income	-130.81M	P/S	11.03	EPS this Y	-8.80%	Inst Trans	25.83%	Short Ratio	1.86	Perf Half Y	31.38%
Sales	35.00M	P/B	0.69	EPS next Y	55.20%	ROA	-20.30%	Short Interest	3.07M	Perf YTD	31.38%
Book/sh	14.72	P/C	0.74	EPS next 5Y	3.89%	ROE	-23.68%	52W High	18.13 -44.35%	Perf Year	-42.24%
Cash/sh	13.60	P/FCF	-	EPS past 3/5Y	- -34.39%	ROIC	-23.07%	52W Low	4.80 110.21%	Perf 3Y	-60.74%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-53.35% -	Gross Margin	96.41%	Volatility	0.59% 1.08%	Perf 5Y	-42.57%
Dividend TTM	-	EV/Sales	-3.69	EPS Y/Y TTM	14.60%	Oper. Margin	-435.19%	ATR (14)	0.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.13	Sales Y/Y TTM	177.89%	Profit Margin	-373.75%	RSI (14)	52.38	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	14.13	EPS Q/Q	24.92%	SMA20	-0.91%	Beta	1.49	Target Price	12.71
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	1.05%	Rel Volume	0.93	Prev Close	10.14
Employees	173	LT Debt/Eq	0.01	Earnings	Apr 28 AMC	SMA200	23.28%	Avg Volume	1.65M	Price	10.09
IPO	Jul 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.79% -100.00%	Trades		Volume	1,542,827	Change	-0.49%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$12
May-28-25	Downgrade	Wedbush	Outperform → Neutral	$12
May-14-25	Downgrade	Leerink Partners	Outperform → Market Perform	$9
May-14-25	Downgrade	H.C. Wainwright	Buy → Neutral
May-13-25	Downgrade	JP Morgan	Overweight → Neutral
Aug-13-24	Initiated	Wells Fargo	Overweight	$31
May-05-21	Initiated	H.C. Wainwright	Buy	$37
Oct-08-20	Initiated	Robert W. Baird	Outperform	$45
Aug-18-20	Initiated	Wedbush	Outperform	$45
Aug-18-20	Initiated	SVB Leerink	Outperform	$45
Aug-18-20	Initiated	Piper Sandler	Overweight	$50
Aug-18-20	Initiated	JP Morgan	Overweight	$40

Show Previous Ratings

Jul-22-25 07:35AM	Replimune drug rejected by FDA; Omega raises $647M biotech fund (BioPharma Dive)
Jul-21-25 07:29AM	iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right (GlobeNewswire)
May-30-25 12:00PM	iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know (Zacks)
May-29-25 07:59AM	iTeos to shut down following $2bn GSK-partnered TIGIT asset failure (Pharmaceutical Technology)
May-28-25 08:30AM	iTeos Therapeutics Announces Its Intention to Wind Down Operations (GlobeNewswire) +17.94%
08:10AM	Loading…
08:10AM	Cancer drugmaker iTeos to shut down (BioPharma Dive)
May-15-25 07:55AM	GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug (Zacks)
May-14-25 06:00AM	GSK and iTeos drop anti-TIGIT drug following trial failure (Clinical Trials Arena)
May-13-25 12:35PM	iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile (Benzinga) +13.44%
07:55AM	iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients (GlobeNewswire)
07:10AM	iTeos, GSK to shelve TIGIT drug after study setback (BioPharma Dive)
May-02-25 09:55AM	Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High? (Zacks)
Apr-28-25 04:30PM	iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-25-25 04:35PM	iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 (GlobeNewswire) -5.44%
Mar-13-25 09:55AM	Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet (Zacks)
07:00AM	Loading…
Mar-05-25 07:00AM	iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire) +5.99%
Jan-13-25 12:00PM	All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy (Zacks)
Jan-10-25 07:00AM	iTeos Announces 2025 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Jan-08-25 07:00AM	iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-24 07:20AM	iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo (TipRanks)
Dec-13-24 01:25PM	Inupadenant deprioritised by iTeos in favour of pipeline TIGIT therapy (Clinical Trials Arena)
Dec-12-24 08:55AM	iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress (GlobeNewswire)
Nov-26-24 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 07:00AM	iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-24-24 07:00AM	iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress (GlobeNewswire)
Oct-16-24 01:01AM	BOXER CAPITAL, LLC Expands Stake in ITeos Therapeutics Inc (GuruFocus.com)
Sep-30-24 01:01PM	TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics Inc (GuruFocus.com)
Sep-16-24 04:04PM	Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths (Investor's Business Daily) -27.54%
Sep-15-24 09:12PM	ESMO 2024: TIGIT race tightens with first look at GSK/iTeoss TIGIT in NSCLC (Pharmaceutical Technology)
Sep-14-24 08:10AM	TIGIT drug from iTeos shrinks lung tumors in trial (BioPharma Dive)
02:30AM	Loading…
02:30AM	iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients (GlobeNewswire)
Aug-28-24 04:30PM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-20-24 08:30AM	iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024 (GlobeNewswire) +10.13%
Aug-08-24 08:20AM	ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-05-24 07:00AM	iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer (GlobeNewswire)
Jul-09-24 12:33PM	iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial (Pharmaceutical Technology)
Jul-08-24 07:00AM	iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK (GlobeNewswire)
Jun-18-24 06:33AM	iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC (Clinical Trials Arena)
Jun-17-24 09:00AM	iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer (GlobeNewswire) -6.04%
May-13-24 08:28AM	HC Wainwright Adjusts Price Target on iTeos Therapeutics to $46 From $44, Maintains Buy Rating (MT Newswires)
May-10-24 01:53PM	ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +43.07%
12:21PM	Wedbush Adjusts iTeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating (MT Newswires)
09:40AM	iTeos Therapeutics Q1 Net Loss Widens; Initiates $120 Million Registered Direct Offering -- Shares Jump (MT Newswires)
08:26AM	iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
08:24AM	iTeos Therapeutics Announces $120 Million Registered Direct Offering (GlobeNewswire)
08:09AM	iTeos shares jump on TIGIT update; Acelyrin swaps CEOs (BioPharma Dive)
Apr-07-24 04:30PM	iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-06-24 02:51PM	ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +7.80%
07:01AM	iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors (GlobeNewswire)
07:00AM	iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-24 04:30PM	iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-01-24 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.23%
Feb-26-24 06:11AM	Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength? (Zacks)
Jan-08-24 07:00AM	iTeos Announces 2024 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Jan-03-24 07:00AM	iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-23 09:55AM	Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade (Zacks)
Nov-27-23 09:55AM	Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect? (Zacks) -5.44%
Nov-21-23 07:00AM	iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-13-23 09:55AM	Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher (Zacks)
Nov-10-23 09:55AM	Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know (Zacks)
Nov-07-23 07:00AM	iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-31-23 03:01AM	Viridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar? (Zacks) +7.48%
Oct-16-23 01:46PM	Hedge Fund and Insider Trading News: Ken Griffin, EcoR1 Capital, Glen Point Capital, JAT Capital, Eisler Capital, Elliott Management, iTeos Therapeutics Inc (ITOS), Funko, Inc. (FNKO), and More (Insider Monkey)
04:38AM	iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar? (Zacks)
Oct-11-23 05:55PM	NCR Atleos Set to Join S&P SmallCap 600 (PR Newswire) -6.72% -6.39%
Sep-06-23 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-23 11:02AM	BOXER CAPITAL, LLC Reduces Stake in ITeos Therapeutics Inc (GuruFocus.com)
Aug-24-23 11:30AM	Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak (Zacks)
Aug-23-23 04:10PM	Why Roche's Accidental Cancer Update Boosted Several Rivals By As Much As 22% (Investor's Business Daily) +14.89%
02:00PM	Watertown biotech shares spike after accidental data publication at Roche (American City Business Journals)
09:24AM	How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30% (Investor's Business Daily)
Aug-08-23 07:00AM	iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jun-21-23 08:00PM	ITOS: Lowering target price to $11.00 (Argus Research)
May-13-23 08:03AM	Broker Revenue Forecasts For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Are Surging Higher (Simply Wall St.)
May-11-23 06:11AM	iTeos Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-10-23 08:35AM	ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:01AM	iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
May-05-23 08:51AM	iTeos Therapeutics (NASDAQ:ITOS) shareholders have endured a 46% loss from investing in the stock a year ago (Simply Wall St.)
Apr-26-23 08:00PM	ITOS: What does Argus have to say about ITOS? (Argus Research)
Mar-23-23 01:56PM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Mar-21-23 06:07AM	Take Care Before Jumping Onto iTeos Therapeutics, Inc. (NASDAQ:ITOS) Even Though It's 25% Cheaper (Simply Wall St.)
Mar-17-23 06:18AM	Time To Worry? Analysts Are Downgrading Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Outlook (Simply Wall St.)
Mar-15-23 08:35AM	ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:00AM	iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-28-23 07:00AM	iTeos to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-07-23 01:51PM	The 7 Best Biotech Stocks to Buy for February 2023 (InvestorPlace)
07:00AM	iTeos to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-02-23 02:19PM	The 7 Most Undervalued Biotech Stocks to Buy in February 2023 (InvestorPlace)
Jan-09-23 07:00AM	iTeos Provides Business Updates and Clinical Development Plans for 2023 (GlobeNewswire)
Jan-03-23 07:00AM	iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.07%
Dec-07-22 08:07AM	Could The Market Be Wrong About iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Its Attractive Financial Prospects? (Simply Wall St.)
Nov-22-22 07:00AM	iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) -5.98%
Nov-10-22 07:55PM	ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates (Zacks) +11.14%
04:01PM	iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-04-22 05:46PM	Top Biotech Stocks for Q4 2022 (Investopedia)
Nov-02-22 10:00AM	ITeos Therapeutics, Inc. (ITOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-18-22 08:36AM	Shareholders in iTeos Therapeutics (NASDAQ:ITOS) are in the red if they invested a year ago (Simply Wall St.)
Aug-12-22 06:16AM	iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.) +7.00%
Aug-10-22 05:25PM	ITeos Therapeutics, Inc. (ITOS) Q2 Earnings and Revenues Lag Estimates (Zacks) -12.51%

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Detheux Michel	Chief Executive Officer	Jun 10 '25	Option Exercise	4.30	137,910	593,013	94,027	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 09 '25	Option Exercise	4.30	43,882	188,693	43,882	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 10 '25	Option Exercise	4.30	26,400	113,520	153,903	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 09 '25	Option Exercise	4.30	8,400	36,120	144,303	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 09 '25	Sale	10.03	43,882	440,136	0	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 10 '25	Sale	10.02	43,883	439,708	0	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 09 '25	Sale	10.03	8,400	84,252	135,903	Jun 11 09:01 PM
Detheux Michel	Chief Executive Officer	Jun 10 '25	Sale	10.02	8,400	84,168	135,903	Jun 11 09:01 PM
Detheux Michel	Officer	Jun 10 '25	Proposed Sale	10.02	52,283	523,876		Jun 10 04:19 PM
Detheux Michel	Officer	Jun 09 '25	Proposed Sale	10.17	52,282	531,708		Jun 09 04:12 PM
Detheux Michel	Chief Executive Officer	Jun 04 '25	Option Exercise	4.30	43,883	188,697	43,883	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 06 '25	Option Exercise	4.30	43,882	188,693	43,882	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 05 '25	Option Exercise	4.30	43,882	188,693	43,882	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 05 '25	Option Exercise	4.30	8,400	36,120	144,303	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 04 '25	Option Exercise	4.30	8,400	36,120	144,303	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 06 '25	Option Exercise	4.30	8,400	36,120	144,303	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 06 '25	Sale	10.21	43,882	448,035	0	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 05 '25	Sale	10.15	43,882	445,402	0	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 04 '25	Sale	10.10	43,883	443,218	0	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 06 '25	Sale	10.21	8,400	85,764	135,903	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 05 '25	Sale	10.15	8,400	85,260	135,903	Jun 06 09:03 PM
Detheux Michel	Chief Executive Officer	Jun 04 '25	Sale	10.10	8,400	84,840	135,903	Jun 06 09:03 PM
Hallal David	Director	Jun 06 '25	Option Exercise	4.30	38,228	164,380	38,228	Jun 06 09:03 PM
Hallal David	Director	Jun 04 '25	Option Exercise	4.30	38,227	164,376	38,227	Jun 06 09:03 PM
Hallal David	Director	Jun 05 '25	Option Exercise	4.30	38,227	164,376	38,227	Jun 06 09:03 PM
Hallal David	Director	Jun 06 '25	Sale	10.24	38,228	391,455	0	Jun 06 09:03 PM
Hallal David	Director	Jun 05 '25	Sale	10.15	38,227	388,004	0	Jun 06 09:03 PM
Hallal David	Director	Jun 04 '25	Sale	10.07	38,227	384,946	0	Jun 06 09:03 PM
Detheux Michel	Officer	Jun 06 '25	Proposed Sale	10.19	52,282	532,754		Jun 06 04:11 PM
DAVID L HALLAL	Director	Jun 06 '25	Proposed Sale	10.24	38,228	391,489		Jun 06 04:09 PM
DAVID L HALLAL	Director	Jun 05 '25	Proposed Sale	10.15	38,227	388,103		Jun 05 04:27 PM
Detheux Michel	Officer	Jun 05 '25	Proposed Sale	10.22	52,282	534,322		Jun 05 04:10 PM
Detheux Michel	Officer	Jun 04 '25	Proposed Sale	10.06	52,283	525,967		Jun 04 04:03 PM
DAVID L HALLAL	Director	Jun 04 '25	Proposed Sale	10.07	38,227	384,782		Jun 04 04:03 PM
EcoR1 Capital, LLC	10% Owner	May 15 '25	Buy	8.00	3,300,000	26,400,000	10,688,978	May 16 06:52 PM
EcoR1 Capital, LLC	10% Owner	May 14 '25	Buy	7.41	1,658,978	12,285,562	7,388,978	May 16 06:52 PM
GADICKE ANSBERT	Former 10% Owner	May 13 '25	Sale	8.06	1,031,931	8,317,364	3,452,797	May 15 05:34 PM
MPM BIOVENTURES 2018, L.P.	Former 10% Owner	May 13 '25	Sale	8.06	630,191	5,079,339	2,108,594	May 15 05:33 PM
MPM BioVentures 2014, L.P.	Former 10% Owner	May 13 '25	Sale	8.06	630,191	5,079,339	2,108,594	May 15 05:32 PM
Van Hauwermeiren Timothy	Director	May 13 '25	Option Exercise	4.30	22,346	96,088	22,346	May 14 08:00 PM
Gall Matthew	Chief Financial Officer	Nov 19 '24	Buy	7.73	5,000	38,635	65,429	Nov 19 07:59 PM

Dollar change -0.06
Percentage change -0.87	%

PRTA Prothena Corporation plc daily Stock Chart

Peers: VRTX BIIB ALNY IONS SRPT NBIX EXEL ACAD ARWR CLDX

| Held by: IWM VXF IWN IBB SCHA VTWO ESML DFAS DFAT VHT

Index	RUT	P/E	-	EPS (ttm)	-2.08	Insider Own	21.38%	Shs Outstand	53.83M	Perf Week	1.95%
Market Cap	366.56M	Forward P/E	-	EPS next Y	-2.33	Insider Trans	-34.54%	Shs Float	42.32M	Perf Month	7.75%
Enterprise Value	-41.18M	PEG	-	EPS next Q	-1.25	Inst Own	70.62%	Short Float	11.24%	Perf Quarter	-21.90%
Income	-110.27M	P/S	2.66	EPS this Y	-71.81%	Inst Trans	-29.14%	Short Ratio	2.65	Perf Half Y	-53.67%
Sales	137.94M	P/B	0.84	EPS next Y	40.19%	ROA	-19.72%	Short Interest	4.76M	Perf YTD	-50.83%
Book/sh	8.13	P/C	0.88	EPS next 5Y	-1.63%	ROE	-23.46%	52W High	23.66 -71.22%	Perf Year	-70.56%
Cash/sh	7.76	P/FCF	-	EPS past 3/5Y	- -3.15%	ROIC	-24.76%	52W Low	4.32 57.64%	Perf 3Y	-78.62%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-12.33% 178.00%	Gross Margin	97.39%	Volatility	5.37% 4.61%	Perf 5Y	-46.92%
Dividend TTM	-	EV/Sales	-0.30	EPS Y/Y TTM	36.41%	Oper. Margin	-100.49%	ATR (14)	0.35	Perf 10Y	-89.38%
Dividend Ex-Date	-	Quick Ratio	9.00	Sales Y/Y TTM	54.55%	Profit Margin	-79.94%	RSI (14)	59.65	Recom	2.12
Dividend Gr. 3/5Y	- -	Current Ratio	9.00	EPS Q/Q	16.85%	SMA20	3.67%	Beta	-0.03	Target Price	24.29
Payout	-	Debt/Eq	0.02	Sales Q/Q	5556.00%	SMA50	14.00%	Rel Volume	0.47	Prev Close	6.87
Employees	163	LT Debt/Eq	0.02	Earnings	Aug 04 AMC	SMA200	-41.37%	Avg Volume	1.79M	Price	6.81
IPO	Dec 21, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	-15.46% -75.30%	Trades		Volume	840,982	Change	-0.87%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-25	Downgrade	BofA Securities	Neutral → Underperform	$4
May-27-25	Downgrade	Oppenheimer	Outperform → Perform
May-27-25	Downgrade	Jefferies	Buy → Hold	$6
May-27-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-20-24	Initiated	Chardan Capital Markets	Buy	$40
Jan-30-24	Downgrade	BofA Securities	Buy → Neutral	$68 → $38
Dec-12-23	Initiated	Deutsche Bank	Buy	$62
Apr-24-23	Initiated	SVB Securities	Outperform	$80
Jan-27-23	Initiated	Piper Sandler	Overweight	$94
Nov-04-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$52 → $55
Sep-28-22	Upgrade	BofA Securities	Neutral → Buy
Nov-19-21	Initiated	JMP Securities	Mkt Outperform	$77
Jun-18-21	Upgrade	BofA Securities	Underperform → Neutral	$12 → $49
Jun-08-21	Reiterated	Oppenheimer	Outperform	$45 → $54
May-26-21	Initiated	Citigroup	Buy	$39
Feb-26-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$14 → $28
Feb-12-21	Upgrade	Jefferies	Hold → Buy	$15 → $30
Feb-02-21	Upgrade	BTIG Research	Neutral → Buy	$29
Dec-07-20	Initiated	H.C. Wainwright	Buy	$22
Jul-09-20	Upgrade	Oppenheimer	Perform → Outperform	$16

Show Previous Ratings

Jul-30-25 10:01AM	PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains? (Zacks)
Jul-29-25 10:00AM	Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline (Zacks)
Jul-28-25 04:05PM	Prothena to Report Second Quarter 2025 Financial Results on August 4 (Business Wire)
Jul-24-25 10:46AM	Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well (Zacks)
Jul-17-25 01:07PM	AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies (Zacks)
01:51PM	Loading…
Jul-04-25 01:51PM	PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects? (Zacks)
Jun-20-25 07:22AM	Prothena to lay off majority of staff; Zealand shares obesity drug data (BioPharma Dive)
Jun-18-25 04:05PM	Prothena Announces Corporate Restructuring (Business Wire)
Jun-17-25 01:30PM	Roche's Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA) (Insider Monkey)
09:16AM	Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus (TipRanks)
Jun-16-25 10:22AM	Roche, waving off study failures, commits to Phase 3 trials for Parkinsons drug (BioPharma Dive) +11.42%
09:49AM	RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development (Zacks)
01:06AM	Prothenas Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease (Business Wire)
May-29-25 03:40PM	Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails (Insider Monkey)
May-28-25 01:55PM	Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform (Insider Monkey)
01:08PM	Loading…
May-27-25 01:08PM	Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results (Insider Monkey) -30.40%
10:20AM	Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down (Zacks)
07:53AM	Biogen strikes RNAi deal with City; Aurion withdraws IPO (BioPharma Dive)
07:43AM	Why Is Prothena Stock Trading Lower On Tuesday? (Benzinga)
May-26-25 06:16AM	Prothenas Phase III trial for AL amyloidosis treatment misses endpoint (Clinical Trials Arena)
May-23-25 04:05PM	Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint (Business Wire) -30.40%
May-09-25 01:28PM	Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025 (Zacks)
08:29AM	Is Prothena Corporation plc (PRTA) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-08-25 05:50PM	Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:47PM	Prothena: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
May-07-25 12:44PM	Prothena Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 04:05PM	Prothena to Report First Quarter 2025 Financial Results on May 8 (Business Wire) -5.22%
Apr-16-25 11:49AM	Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi (Zacks)
Feb-21-25 02:15AM	Prothena Corp PLC (PRTA) Q4 2024 Earnings Call Highlights: Strong Financial Position Amidst ... (GuruFocus.com)
05:25PM	Loading…
Feb-20-25 05:25PM	Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:22PM	Prothena: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights (Business Wire)
Feb-13-25 04:05PM	Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 (Business Wire)
Dec-30-24 04:05PM	Prothena Announces Board of Directors Update (Business Wire) -6.92%
Dec-19-24 04:22PM	Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease (Investor's Business Daily) +33.97%
08:09AM	Prothenas Parkinsons study fails primary endpoint despite some success (Clinical Trials Arena)
01:05AM	Roches Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinsons Disease (Business Wire)
Dec-12-24 11:30AM	Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report? (Zacks)
Nov-12-24 05:55PM	Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:56PM	Prothena: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire)
Nov-05-24 04:05PM	Prothena to Report Third Quarter 2024 Financial Results on November 12 (Business Wire) +8.71%
Oct-29-24 12:00PM	Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
04:48AM	Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength? (Zacks)
Oct-18-24 03:01PM	State Street Corp's Strategic Reduction in Prothena Corp PLC Holdings (GuruFocus.com)
Sep-27-24 04:05PM	Prothena Announces Leadership Team Updates (Business Wire) -16.56%
Aug-29-24 04:05PM	Prothena to Participate in Upcoming Healthcare Conferences (Business Wire)
Aug-19-24 12:00PM	What Makes Prothena (PRTA) a New Buy Stock (Zacks)
Aug-18-24 12:28AM	Prothena Corporation plc (PTRA): Positioning Among Top Debt-Free Stocks (Insider Monkey)
Aug-17-24 08:22AM	7 Best Debt Free Stocks To Buy (Insider Monkey)
Aug-09-24 09:16AM	Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues (Zacks)
Aug-08-24 06:40PM	Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates (Zacks)
05:33PM	Prothena: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire)
Aug-01-24 04:05PM	Prothena to Report Second Quarter 2024 Financial Results on August 8 (Business Wire) -5.20%
Jul-25-24 10:02AM	Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jun-24-24 08:48AM	Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last? (Zacks)
Jun-11-24 04:07PM	Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower (Investor's Business Daily)
12:20PM	Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win (Investor's Business Daily)
Jun-07-24 11:30AM	Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report? (Zacks)
May-29-24 10:26AM	Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate (Zacks)
08:46AM	BMS stakes $80m on Prothenas neurodegenerative candidate (Pharmaceutical Technology)
May-28-24 04:05PM	Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration (Business Wire)
May-09-24 11:52AM	Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses (Zacks)
May-08-24 10:56PM	PRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:10PM	Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
05:14PM	Prothena: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
May-01-24 04:05PM	Prothena to Report First Quarter 2024 Financial Results on May 8 (Business Wire) +5.31%
Apr-25-24 10:01AM	Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline (Zacks)
Apr-15-24 04:05PM	Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma (Business Wire)
Mar-28-24 08:00AM	Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback (Investor's Business Daily)
Mar-05-24 04:05PM	Prothena to Participate in Upcoming Healthcare Conferences (Business Wire)
Mar-04-24 04:05PM	Prothena Appoints David Ford to Newly Created Chief People Officer Position (Business Wire)
Feb-21-24 04:05PM	Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate (Business Wire)
Feb-16-24 01:33PM	Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense (Zacks)
10:33AM	Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-15-24 04:50PM	Prothena: Q4 Earnings Snapshot (Associated Press Finance)
04:48PM	Prothena Corp PLC (PRTA) Reports 2023 Financial Results and Provides 2024 Outlook (GuruFocus.com)
04:05PM	Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights (Business Wire)
Feb-08-24 04:05PM	Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024 (Business Wire)
Jan-24-24 11:02PM	Prothena Corp PLC Chief Accounting Officer Sells 5,000 Shares (GuruFocus.com)
Jan-10-24 12:06PM	Prothena's (PRTA) Update on Pipeline Progress Disappoints (Zacks) -9.46%
05:38AM	Prothena (PRTA) Surges 12.3%: Is This an Indication of Further Gains? (Zacks)
Jan-08-24 08:30AM	Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs (Business Wire) -13.23%
Dec-21-23 09:01AM	Prothena Corp PLC Chief Accounting Officer Sells Company Shares (GuruFocus.com)
Dec-17-23 05:41AM	These 3 Biotech Stocks Have Strong Upside Potential, Says Deutsche Bank (TipRanks)
Dec-01-23 11:05AM	Insider Sell Alert: Karin Walker of Prothena Corp PLC Cashes Out 5,000 Shares (GuruFocus.com) +7.09%
Nov-29-23 08:35AM	Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks (Investor's Business Daily)
Nov-20-23 06:00AM	FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug success (Reuters)
Nov-17-23 01:35PM	Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market (Zacks)
08:15AM	Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning (Investor's Business Daily)
Nov-03-23 11:34AM	Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike (Zacks) +7.41%
Nov-02-23 07:03PM	Prothena Corp PLC (PRTA) Reports Q3 2023 Financial Results (GuruFocus.com)
06:25PM	Prothena (PRTA) Beats Q3 Earnings and Revenue Estimates (Zacks)
05:24PM	Prothena: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Oct-30-23 10:00AM	Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-26-23 04:09PM	Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment (Investor's Business Daily) -14.62% +5.52%

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EcoR1 Capital, LLC	10% Owner	May 02 '25	Sale	8.36	3,317,938	27,744,929	8,266,342	May 06 07:06 PM
EcoR1 Capital, LLC	10% Owner	May 06 '25	Sale	7.64	1,984,053	15,164,712	5,304,596	May 06 07:06 PM
EcoR1 Capital, LLC	10% Owner	May 05 '25	Sale	8.11	977,693	7,930,166	7,288,649	May 06 07:06 PM
SCULLY WILLIAM P	10% Owner	Jan 14 '25	Buy	12.79	100,000	1,279,040	735,993	May 02 10:29 AM
SCULLY WILLIAM P	10% Owner	Dec 18 '24	Buy	13.93	73,436	1,022,670	1,297,693	May 02 10:29 AM
SCULLY WILLIAM P	10% Owner	Dec 31 '24	Buy	13.01	32,000	416,393	650,193	May 02 10:29 AM
SCULLY WILLIAM P	10% Owner	Dec 20 '24	Buy	15.91	2,000	31,813	618,693	May 02 10:29 AM

Open in Screener

ANAB

AnaptysBio Inc

Aug 01 • 04:00PM ET

24.69

Dollar change +0.14
Percentage change 0.57	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX BMRN ALNY IONS SRPT EXEL BLUE INCY RGEN

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA PTH IWC

Index	RUT	P/E	-	EPS (ttm)	-4.84	Insider Own	10.01%	Shs Outstand	30.39M	Perf Week	-8.35%
Market Cap	725.40M	Forward P/E	-	EPS next Y	-4.97	Insider Trans	-0.91%	Shs Float	26.44M	Perf Month	3.39%
Enterprise Value	731.42M	PEG	-	EPS next Q	-1.55	Inst Own	128.16%	Short Float	35.48%	Perf Quarter	13.78%
Income	-140.62M	P/S	6.48	EPS this Y	-4.52%	Inst Trans	23.42%	Short Ratio	16.13	Perf Half Y	41.73%
Sales	111.87M	P/B	22.05	EPS next Y	7.17%	ROA	-33.97%	Short Interest	9.38M	Perf YTD	86.48%
Book/sh	1.12	P/C	2.13	EPS next 5Y	-2.22%	ROE	-343.83%	52W High	41.31 -40.23%	Perf Year	-28.93%
Cash/sh	11.57	P/FCF	-	EPS past 3/5Y	-34.42% -7.30%	ROIC	-37.20%	52W Low	12.21 102.21%	Perf 3Y	12.89%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	13.05% 62.73%	Gross Margin	97.86%	Volatility	5.39% 4.94%	Perf 5Y	24.13%
Dividend TTM	-	EV/Sales	6.54	EPS Y/Y TTM	21.00%	Oper. Margin	-89.64%	ATR (14)	1.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.25	Sales Y/Y TTM	387.20%	Profit Margin	-125.70%	RSI (14)	45.70	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	8.25	EPS Q/Q	21.71%	SMA20	-4.88%	Beta	-0.19	Target Price	49.00
Payout	-	Debt/Eq	10.17	Sales Q/Q	286.84%	SMA50	3.06%	Rel Volume	0.56	Prev Close	24.55
Employees	136	LT Debt/Eq	10.11	Earnings	May 05 AMC	SMA200	19.35%	Avg Volume	581.60K	Price	24.69
IPO	Jan 26, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.15% 81.82%	Trades		Volume	326,862	Change	0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-04-25	Upgrade	H.C. Wainwright	Neutral → Buy	$38
Feb-04-25	Initiated	Wolfe Research	Outperform	$25
Dec-11-24	Downgrade	H.C. Wainwright	Buy → Neutral	$52 → $19
Dec-02-24	Downgrade	BTIG Research	Buy → Neutral
Jul-22-24	Initiated	H.C. Wainwright	Buy	$55
Jul-19-24	Upgrade	JP Morgan	Neutral → Overweight	$29 → $69
Apr-16-24	Initiated	Leerink Partners	Outperform	$47
Apr-11-24	Initiated	Wells Fargo	Overweight	$56
Mar-12-24	Upgrade	Wedbush	Neutral → Outperform	$20 → $34
Feb-26-24	Initiated	BTIG Research	Buy	$55
Feb-21-24	Initiated	Stifel	Buy	$50
Feb-16-24	Initiated	Piper Sandler	Overweight	$80
May-22-23	Upgrade	JP Morgan	Underweight → Neutral	$31 → $30
May-18-23	Initiated	TD Cowen	Outperform
Jan-06-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-01-22	Upgrade	Guggenheim	Neutral → Buy	$44
Sep-19-22	Resumed	H.C. Wainwright	Buy	$35
Sep-13-22	Downgrade	Truist	Buy → Hold	$50 → $28
Sep-01-22	Initiated	Raymond James	Outperform	$35
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral

Show Previous Ratings

Jul-29-25 10:00AM	AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jun-03-25 04:05PM	Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA (GlobeNewswire) +7.59% -9.57%
May-27-25 04:15PM	Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 (GlobeNewswire)
May-12-25 03:53PM	AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now (Insider Monkey)
May-05-25 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:15PM	Loading…
04:15PM	Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-17-25 07:00AM	Bright Peak Therapeutics Appoints John Schmid to its Board of Directors (GlobeNewswire) +7.82%
Mar-25-25 09:21AM	AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last? (Zacks)
Mar-24-25 09:15AM	Anaptys Announces Stock Repurchase Plan (GlobeNewswire) +9.54%
Mar-16-25 06:05AM	Wells Fargo Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Feb-27-25 06:55PM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Participation in March Investor Conferences (GlobeNewswire)
04:15PM	Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-13-25 10:00AM	Truist says AnaptysBio handing of placebo raise doubt about Phase 2 RA data (TipRanks) +19.44%
09:40AM	Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year? (Zacks)
05:11AM	Loading…
05:11AM	AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains? (Zacks)
Feb-12-25 12:22PM	AnaptysBio achieves highest ever results in Phase II rheumatoid arthritis trial (Clinical Trials Arena) +30.51%
09:23AM	AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment (Investor's Business Daily)
07:30AM	Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months (GlobeNewswire)
Feb-11-25 05:30PM	Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025 (GlobeNewswire)
Feb-04-25 06:37AM	Vanda and AnaptysBio link for generalised pustular psoriasis therapy (Pharmaceutical Technology)
Feb-03-25 04:15PM	Anaptys to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire) -7.08%
07:30AM	Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist (PR Newswire)
Jan-27-25 09:40AM	Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? (Zacks)
Jan-13-25 09:42AM	How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry (Zacks)
Jan-12-25 03:00AM	Big Biotech Fund Loads Up on a Stock That Surged in 2024, and a Loser (Barrons.com)
Jan-07-25 09:15AM	Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-24 05:23AM	AnaptysBios atopic dermatitis trial of BTLA agonist misses endpoints (Clinical Trials Arena)
Dec-11-24 02:07PM	AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data (Benzinga) -32.83%
08:30AM	Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis (GlobeNewswire)
09:40AM	Loading…
Nov-25-24 09:40AM	Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? (Zacks) +8.22%
Nov-08-24 12:00PM	AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:35AM	Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB) (Zacks)
Nov-05-24 05:30PM	AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +11.72%
04:15PM	Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:15PM	Anaptys Announces Participation in November and December Investor Conferences (GlobeNewswire)
Aug-29-24 09:15AM	Anaptys Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-23-24 07:26AM	Why AnaptysBio Was Such a Healthy Stock This Week (Motley Fool)
Aug-14-24 04:11PM	AnaptysBio Surges After Sanofi Takes A Stake In $100 Million Offering (Investor's Business Daily) -6.35%
10:05AM	AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering (Investor's Business Daily)
05:00AM	Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering (GlobeNewswire)
Aug-05-24 09:54PM	ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:55PM	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-24 10:00AM	AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jul-22-24 02:53PM	AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst (Benzinga) +5.96%
May-09-24 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -10.75%
04:15PM	Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:10PM	Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) (GlobeNewswire)
04:05PM	Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties (GlobeNewswire)
May-02-24 10:01AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
May-01-24 04:51AM	AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks) +6.90%
Apr-24-24 09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Apr-15-24 02:19PM	BTIG Research Predicts Over 118% Rally for These 3 Stocks (InvestorPlace) -6.34%
Apr-12-24 07:00PM	Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week (Motley Fool) -8.17%
Apr-09-24 02:40PM	Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock. (Zacks)
Mar-14-24 12:00PM	What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade (Zacks)
Mar-11-24 05:30PM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.85% +11.61%
04:15PM	Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-29-24 09:15AM	Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting (GlobeNewswire)
Feb-28-24 10:00AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-22-24 04:00AM	13 Best Short Squeeze Stocks To Buy Now (Insider Monkey)
Feb-19-24 05:54AM	Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength? (Zacks)
Jan-31-24 09:15AM	Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-12-24 03:02PM	AnaptysBio Inc CEO Daniel Faga Sells 6,866 Shares (GuruFocus.com)
Dec-07-23 09:55AM	Does AnaptysBio, Inc. (ANAB) Have the Potential to Rally 69.36% as Wall Street Analysts Expect? (Zacks)
Nov-27-23 04:15PM	Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals (GlobeNewswire)
Nov-14-23 09:35AM	Down -24.46% in 4 Weeks, Here's Why AnaptysBio, Inc. (ANAB) Looks Ripe for a Turnaround (Zacks) +7.29%
Nov-07-23 04:15PM	Anaptys Named a BioSpace 2024 Best Places to Work Winner (GlobeNewswire) -6.17%
Nov-04-23 05:41AM	AnaptysBio Inc (ANAB) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
Nov-02-23 04:15PM	Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +8.21%
Nov-01-23 09:15AM	Anaptys Announces Participation in November Investor Conferences (GlobeNewswire)
Oct-11-23 09:15AM	Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress (GlobeNewswire)
Oct-09-23 08:27AM	UPDATE 1-AnaptysBio's skin disease drug meets main goal in late-stage study (Reuters)
08:15AM	Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25 (GlobeNewswire)
08:05AM	AnaptysBio's skin disease drug meets main goal in late-stage study (Reuters)
08:00AM	Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) (GlobeNewswire)
Sep-19-23 03:01PM	Insider Sell: Eric Loumeau Sells 6,000 Shares of AnaptysBio Inc (GuruFocus.com)
Sep-18-23 04:15PM	AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors (GlobeNewswire)
Sep-12-23 09:15AM	AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit (GlobeNewswire)
Aug-07-23 04:15PM	AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-23 01:34PM	AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer (GlobeNewswire) +15.13%
Jul-04-23 06:22AM	Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested five years ago (Simply Wall St.)
May-30-23 04:15PM	AnaptysBio Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-24-23 06:01AM	Need To Know: The Consensus Just Cut Its AnaptysBio, Inc. (NASDAQ:ANAB) Estimates For 2023 (Simply Wall St.)
May-22-23 01:44AM	4 big analyst picks: Norfolk Southern stock pops on 2 upgrades (Investing.com)
May-11-23 05:35PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.31%
04:15PM	AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update (GlobeNewswire)
May-04-23 09:55AM	Wall Street Analysts Predict a 45.12% Upside in AnaptysBio, Inc. (ANAB): Here's What You Should Know (Zacks)
May-02-23 09:15AM	AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP) (GlobeNewswire)
Apr-30-23 09:47AM	When Will AnaptysBio, Inc. (NASDAQ:ANAB) Breakeven? (Simply Wall St.)
Apr-27-23 10:02AM	Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-26-23 10:02AM	Will AnaptysBio, Inc. (ANAB) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-14-23 03:13AM	CRISPR Therapeutics AG (CRSP) Soars 16.3%: Is Further Upside Left in the Stock? (Zacks)
Apr-06-23 04:15PM	AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors (GlobeNewswire)
Apr-03-23 07:14AM	Companies Like AnaptysBio (NASDAQ:ANAB) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-27-23 06:50PM	AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial (GlobeNewswire)
Mar-01-23 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RENTON HOLLINGS	Director	Jul 02 '25	Option Exercise	6.93	20,925	145,010	25,890	Jul 03 01:34 PM
RENTON HOLLINGS	Director	Jul 02 '25	Sale	23.57	20,925	493,191	4,965	Jul 03 01:34 PM
HOLLINGS C RENTON	Director	Jul 02 '25	Proposed Sale	23.57	20,925	493,190		Jul 02 04:13 PM
FENTON DENNIS M	Director	Jun 18 '25	Sale	23.97	3,015	72,270	4,965	Jun 20 04:07 PM
RENTON HOLLINGS	Director	Jun 18 '25	Sale	23.97	3,015	72,270	4,965	Jun 20 04:06 PM
HOLLINGS C RENTON	Director	Jun 18 '25	Proposed Sale	23.97	3,015	72,270		Jun 18 04:26 PM
DENNIS M FENTON	Director	Jun 18 '25	Proposed Sale	23.97	3,015	72,270		Jun 18 04:06 PM
Jain Rita	Director	Jun 15 '25	Option Exercise	0.00	7,330	0	11,864	Jun 17 06:33 PM
FENTON DENNIS M	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	7,980	Jun 17 06:33 PM
Marquet Magda	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	9,930	Jun 17 06:32 PM
Orwin John A	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	9,365	Jun 17 06:31 PM
RENTON HOLLINGS	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	7,980	Jun 17 06:30 PM
Schmid John P.	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	52,267	Jun 17 06:30 PM
Ware J. Anthony	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	13,530	Jun 17 06:29 PM
Schmid John P.	Director	Jan 13 '25	Option Exercise	6.50	42,337	275,007	46,237	Jan 15 05:04 PM
EcoR1 Capital, LLC	Director	Dec 30 '24	Buy	12.92	65,184	842,060	7,860,180	Jan 02 06:17 PM
EcoR1 Capital, LLC	Director	Dec 31 '24	Buy	12.93	13,268	171,513	7,873,448	Jan 02 06:17 PM
EcoR1 Capital, LLC	Director	Jan 02 '25	Buy	12.95	6,646	86,070	7,880,094	Jan 02 06:17 PM
RENTON HOLLINGS	Director	Nov 29 '24	Option Exercise	6.93	10,000	69,300	11,950	Dec 03 04:35 PM
RENTON HOLLINGS	Director	Nov 29 '24	Sale	25.00	10,000	250,000	1,950	Dec 03 04:35 PM
HOLLINGS C RENTON	Director	Nov 29 '24	Proposed Sale	25.00	10,000	250,000		Nov 29 01:29 PM
Lizzul Paul F.	Chief Medical Officer	Sep 23 '24	Option Exercise	18.50	1,500	27,750	16,898	Sep 24 04:18 PM
Lizzul Paul F.	Chief Medical Officer	Sep 23 '24	Sale	38.67	1,500	58,005	15,398	Sep 24 04:18 PM
PAUL F LIZZUL	Officer	Sep 23 '24	Proposed Sale	38.67	1,500	58,005		Sep 23 04:16 PM
Orwin John A	Director	Sep 15 '24	Option Exercise	0.00	1,300	0	3,335	Sep 17 06:45 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 16 '24	Option Exercise	14.02	5,000	70,100	13,520	Sep 17 06:44 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 14 '24	Option Exercise	0.00	6,000	0	10,740	Sep 17 06:44 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 16 '24	Sale	39.82	8,720	347,270	7,020	Sep 17 06:44 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 17 '24	Sale	38.41	3,780	145,191	3,240	Sep 17 06:44 PM
Lizzul Paul F.	Chief Medical Officer	Sep 16 '24	Sale	38.93	2,220	86,425	15,398	Sep 17 06:42 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Sep 16 '24	Option Exercise	20.16	10,000	201,600	14,744	Sep 17 06:41 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Sep 16 '24	Sale	39.91	12,220	487,725	4,744	Sep 17 06:41 PM
ERIC J LOUMEAU	Officer	Sep 17 '24	Proposed Sale	38.41	3,780	145,191		Sep 17 04:02 PM
DENNIS MULROY	Officer	Sep 16 '24	Proposed Sale	40.13	10,000	401,300		Sep 16 04:33 PM
ERIC J LOUMEAU	Officer	Sep 16 '24	Proposed Sale	40.13	6,500	260,845		Sep 16 04:22 PM
Lizzul Paul F.	Chief Medical Officer	Aug 14 '24	Option Exercise	18.50	2,000	37,000	13,618	Aug 16 04:09 PM
Lizzul Paul F.	Chief Medical Officer	Aug 14 '24	Sale	40.00	2,000	80,000	11,618	Aug 16 04:09 PM
EcoR1 Capital, LLC	10% Owner	Aug 14 '24	Buy	36.50	273,972	9,999,978	7,794,996	Aug 16 12:04 PM
PAUL F LIZZUL	Officer	Aug 14 '24	Proposed Sale	40.00	2,000	80,000		Aug 14 04:34 PM

Open in Screener

TNGX

Tango Therapeutics Inc

Aug 01 • 04:00PM ET

6.53

Dollar change +0.49
Percentage change 8.11	%

Healthcare • Biotechnology • USA • NASD

TNGX Tango Therapeutics Inc daily Stock Chart

Peers: CRSP NTLA BEAM KRYS PLRX EDIT SGMO FDMT AFMD VCNX

| Held by: VTI IWM VXF IWN IBB VTWO SCHA IWC ITOT VHT

Index	RUT	P/E	-	EPS (ttm)	-1.21	Insider Own	45.64%	Shs Outstand	108.11M	Perf Week	-4.25%
Market Cap	707.81M	Forward P/E	-	EPS next Y	-1.29	Insider Trans	-0.09%	Shs Float	58.92M	Perf Month	15.58%
Enterprise Value	527.61M	PEG	-	EPS next Q	-0.34	Inst Own	58.06%	Short Float	36.53%	Perf Quarter	363.12%
Income	-132.26M	P/S	17.27	EPS this Y	-12.29%	Inst Trans	10.91%	Short Ratio	7.12	Perf Half Y	109.97%
Sales	40.99M	P/B	4.23	EPS next Y	3.74%	ROA	-38.87%	Short Interest	21.53M	Perf YTD	111.33%
Book/sh	1.54	P/C	3.26	EPS next 5Y	-5.61%	ROE	-61.35%	52W High	12.02 -45.65%	Perf Year	-32.68%
Cash/sh	2.00	P/FCF	-	EPS past 3/5Y	-8.36% 7.47%	ROIC	-65.84%	52W Low	1.03 533.98%	Perf 3Y	49.77%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.33% 53.11%	Gross Margin	93.91%	Volatility	9.80% 8.05%	Perf 5Y	-
Dividend TTM	-	EV/Sales	12.87	EPS Y/Y TTM	-7.25%	Oper. Margin	-355.86%	ATR (14)	0.53	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.26	Sales Y/Y TTM	10.10%	Profit Margin	-322.67%	RSI (14)	60.33	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	6.26	EPS Q/Q	-3.14%	SMA20	2.77%	Beta	1.64	Target Price	10.43
Payout	-	Debt/Eq	0.22	Sales Q/Q	-16.67%	SMA50	31.55%	Rel Volume	1.73	Prev Close	6.04
Employees	155	LT Debt/Eq	0.20	Earnings	Aug 05 BMO	SMA200	92.23%	Avg Volume	3.02M	Price	6.53
IPO	Sep 03, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.83% -19.84%	Trades		Volume	5,243,857	Change	8.11%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-17-24	Initiated	Jefferies	Buy	$19
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight	$18
Dec-08-23	Initiated	B. Riley Securities	Buy	$16
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy	$10
Sep-20-21	Initiated	SVB Leerink	Outperform	$25

Jul-31-25 07:40PM	IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates (Zacks) +8.11%
Jul-30-25 10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
09:55AM	Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade (Zacks)
Jul-29-25 10:00AM	Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-22-25 07:00AM	Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 (GlobeNewswire)
09:55AM	Loading…
Jul-14-25 09:55AM	Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect? (Zacks)
Jun-30-25 05:47AM	Tango doses first subject in MTAP-deleted and RAS mutant cancer trial (Clinical Trials Arena)
Jun-27-25 07:00AM	Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer (GlobeNewswire)
Jun-23-25 09:07AM	Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? (Zacks)
May-27-25 07:00AM	Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire) +11.41%
May-21-25 07:00AM	Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors (GlobeNewswire) -8.70%
May-12-25 08:15AM	Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +14.91%
07:00AM	Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
May-09-25 09:45AM	Tango Therapeutics Inc (TNGX) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-06-25 08:20AM	Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -11.27%
10:00AM	Loading…
May-05-25 10:00AM	Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) -5.96%
May-01-25 07:00AM	Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (GlobeNewswire)
Apr-09-25 05:00AM	Barbara Weber, M.D., Elected to ITM Supervisory Board (GlobeNewswire) +16.53%
Mar-25-25 04:30PM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire) -5.75% -6.10%
Feb-27-25 07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights (GlobeNewswire) -6.44%
Feb-20-25 07:30AM	Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences (GlobeNewswire)
Jan-30-25 07:00AM	Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference (GlobeNewswire)
Dec-03-24 07:00AM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.14%
Nov-27-24 07:00AM	Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire) +6.25%
Nov-23-24 10:26AM	Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-06-24 07:05AM	Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights (Business Wire) -37.45%
07:00AM	Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program (Business Wire)
Aug-28-24 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Aug-18-24 09:03AM	Jefferies Predicts up to 270% Rally for These 2 Strong Buy Stocks (TipRanks)
Aug-07-24 07:00AM	Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights (Business Wire)
05:10AM	Loading…
Jun-14-24 05:10AM	Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last? (Zacks) +6.44%
Jun-05-24 07:00AM	Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-23-24 09:18AM	Medivirs licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program (PR Newswire)
07:00AM	Tango Therapeutics Announces Discontinuation of TNG348 Program (Business Wire)
May-08-24 01:53PM	TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:10AM	Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights (Business Wire)
May-07-24 10:00AM	Will Tango Therapeutics, Inc. (TNGX) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-01-24 04:48PM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-20-24 05:31AM	Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
Mar-18-24 02:52PM	TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -7.09%
08:10AM	Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights (Business Wire)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Mar-06-24 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Mar-05-24 04:47PM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire)
Feb-07-24 08:55AM	Pancreatic Cancer Treatments Poised for Major Advances in 2024 (PR Newswire)
Jan-31-24 07:00AM	Tango Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-05-24 04:05PM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-24 02:47AM	Medivirs licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study (PR Newswire)
Jan-03-24 07:00AM	Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers (GlobeNewswire)
Nov-13-23 07:00AM	Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting (GlobeNewswire) -9.45%
Nov-08-23 03:12PM	Tango Therapeutics Inc (TNGX) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
07:00AM	Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-07-23 07:00AM	Tango Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-10-23 11:28AM	Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why (Zacks)
Oct-09-23 08:50AM	What Makes Tango Therapeutics, Inc. (TNGX) a Good Fit for 'Trend Investing' (Zacks) -13.27%
Sep-18-23 07:00AM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +5.88%
Sep-06-23 07:00AM	Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers (GlobeNewswire)
Sep-05-23 07:00AM	Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-29-23 05:08PM	Tango Therapeutics Announces Updates to Its Board of Directors (GlobeNewswire) -7.51%
Aug-28-23 07:00AM	Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer (GlobeNewswire)
Aug-10-23 07:00AM	Tango Therapeutics Announces $80 million Private Placement Financing (GlobeNewswire) -16.26%
Aug-07-23 07:00AM	Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Jul-24-23 07:00AM	Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers (GlobeNewswire)
Jul-10-23 07:00AM	Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors (GlobeNewswire)
Jun-01-23 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-23 07:00AM	Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire) +6.40%
Apr-18-23 04:30PM	Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting (GlobeNewswire) -11.67%
Apr-03-23 07:00AM	Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers (GlobeNewswire) +10.38%
Mar-27-23 07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights (GlobeNewswire) -9.35%
Mar-14-23 08:11PM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting (GlobeNewswire)
Mar-10-23 10:15PM	Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank (GlobeNewswire) -13.33% +6.45%
Mar-06-23 07:00AM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-23 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-28-23 07:00AM	Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development (GlobeNewswire) +6.09%
Feb-02-23 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-25-23 07:00AM	Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates (GlobeNewswire)
Dec-15-22 07:00AM	HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors (GlobeNewswire)
Nov-10-22 07:00AM	Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) -5.27%
Nov-07-22 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-19-22 07:00AM	Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-05-22 08:10AM	Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting (GlobeNewswire)
Sep-06-22 07:00AM	Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) -12.62%
Aug-13-22 08:27AM	The Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts (Simply Wall St.)
Aug-10-22 07:00AM	Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +22.41%
Aug-02-22 07:00AM	Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference (GlobeNewswire) +6.30%
Jun-27-22 07:00AM	Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes (GlobeNewswire)
Jun-20-22 07:26AM	We Think Tango Therapeutics (NASDAQ:TNGX) Can Afford To Drive Business Growth (Simply Wall St.)
Jun-08-22 07:00AM	Tango Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference (GlobeNewswire)
May-11-22 07:00AM	Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) -7.57%
May-09-22 07:00AM	Tango Therapeutics to Participate in the Guggenheim Synthetic Lethality Day 2022 (GlobeNewswire) -12.62%
Apr-19-22 07:22AM	Shareholders in Tango Therapeutics (NASDAQ:TNGX) are in the red if they invested a year ago (Simply Wall St.)
Mar-28-22 07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-08-22 04:57PM	Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual Meeting (GlobeNewswire)
Mar-03-22 09:41AM	Tango Therapeutics Announces Presentation of TNG908 Preclinical Combination Data at 2022 ESMO Targeted Anticancer Therapies Congress (GlobeNewswire) -7.42%
Feb-28-22 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-02-22 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-24-22 07:00AM	Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates (GlobeNewswire) +5.30%
Jan-11-22 09:37AM	We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow (Simply Wall St.)

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Barry Douglas	General Counsel	Feb 04 '25	Sale	2.99	2,774	8,289	68,570	Feb 06 08:21 PM
Barry Douglas	General Counsel	Feb 05 '25	Sale	3.16	2,556	8,081	66,014	Feb 06 08:21 PM
Beckman Daniella	Chief Financial Officer	Feb 04 '25	Sale	2.99	4,284	12,801	154,232	Feb 06 08:10 PM
Beckman Daniella	Chief Financial Officer	Feb 05 '25	Sale	3.16	3,948	12,481	150,284	Feb 06 08:10 PM
Crystal Adam	See Remarks	Feb 04 '25	Sale	2.99	7,432	22,207	165,061	Feb 06 08:08 PM
Crystal Adam	See Remarks	Feb 05 '25	Sale	3.16	6,851	21,659	158,210	Feb 06 08:08 PM
Weber Barbara	Chief Executive Officer	Feb 04 '25	Sale	2.99	9,778	29,217	1,631,264	Feb 06 08:02 PM
Weber Barbara	Chief Executive Officer	Feb 05 '25	Sale	3.16	9,013	28,494	1,622,251	Feb 06 08:02 PM
Rothenberg Mace	Director	Nov 18 '24	Buy	3.78	10,000	37,800	31,250	Nov 18 07:20 PM
Rothenberg Mace	Director	Nov 14 '24	Buy	3.62	10,000	36,200	21,250	Nov 18 07:20 PM
EcoR1 Capital, LLC	10% Owner	Nov 06 '24	Sale	3.28	1,494,558	4,896,023	11,836,178	Nov 08 07:24 PM
EcoR1 Capital, LLC	10% Owner	Nov 07 '24	Sale	2.94	1,205,442	3,539,720	10,630,736	Nov 08 07:24 PM
Boxer Capital Management, LLC		Nov 06 '24	Sale	3.14	3,080,000	9,671,200	3,610,642	Nov 07 09:30 PM
Boxer Capital Management, LLC	Member of group formerly ownin	Nov 06 '24	Proposed Sale	5.18	575,000	2,978,500		Nov 06 09:40 PM
Boxer Capital Management, LLC		Oct 25 '24	Sale	6.87	633,000	4,348,710	6,690,642	Oct 28 06:59 AM
Boxer Capital Management, LLC	Member of group owning over 10	Oct 25 '24	Proposed Sale	6.29	100,000	629,000		Oct 25 09:30 PM
Boxer Capital Management, LLC		Oct 21 '24	Sale	7.05	625,000	4,406,250	7,573,642	Oct 23 09:31 PM
Boxer Capital Management, LLC		Oct 22 '24	Sale	6.78	250,000	1,695,000	7,323,642	Oct 23 09:31 PM
Boxer Capital Management, LLC	Member of group owning over 10	Oct 22 '24	Proposed Sale	7.15	127,600	912,340		Oct 22 08:50 PM
Boxer Capital Management, LLC	Member of group owning over 10	Oct 21 '24	Proposed Sale	7.46	500,000	3,730,000		Oct 22 12:03 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 13 '24	Sale	10.53	67,400	709,756	16,859,075	Sep 17 04:48 PM
Third Rock Ventures IV, L.P.	Affiliate	Sep 13 '24	Proposed Sale	10.50	67,400	707,700		Sep 13 05:43 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 05 '24	Sale	11.56	75,000	867,135	16,926,475	Sep 09 07:19 PM
Third Rock Ventures IV, L.P.	Affiliate	Sep 05 '24	Proposed Sale	11.68	75,000	876,000		Sep 05 05:01 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 30 '24	Sale	11.60	175,000	2,029,702	17,001,475	Sep 04 08:42 PM
Third Rock Ventures IV, L.P.	Affiliate	Aug 30 '24	Proposed Sale	11.83	175,000	2,070,250		Aug 30 05:24 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 27 '24	Sale	11.55	25,000	288,665	17,176,475	Aug 29 04:40 PM
Third Rock Ventures IV, L.P.	Affiliate	Aug 27 '24	Proposed Sale	11.40	25,000	285,000		Aug 27 04:53 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 19 '24	Sale	10.09	150,000	1,513,920	17,201,475	Aug 20 05:59 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 16 '24	Sale	9.79	135,000	1,321,448	17,351,475	Aug 20 05:59 PM
Third Rock Ventures IV, L.P.	Affiliate	Aug 19 '24	Proposed Sale	10.68	150,000	1,602,000		Aug 19 05:35 PM
Third Rock Ventures IV, L.P.	Affiliate	Aug 16 '24	Proposed Sale	9.96	135,000	1,344,600		Aug 16 05:14 PM

ADAP

Adaptimmune Therapeutics Plc ADR

ZYME

Zymeworks BC Inc

ITOS

ITeos Therapeutics Inc

PRTA

Prothena Corporation plc

ANAB

AnaptysBio Inc

TNGX

Tango Therapeutics Inc

Upgrade your FINVIZ experience